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In a tuberculosis (TB) program in the Central Penitentiary Hospital of Azer-
baijan, we analyzed 65 isolates of Mycobacterium tuberculosis by IS6110-
based restriction fragment-length polymorphism (RFLP) and spoligotyping.
From 11 clusters associated with 33 patients, 31 isolates had an IS6110-
based banding pattern characteristic of the Beijing genotype of M. tubercu-
losis. In addition, 15 M. tuberculosis isolates with similar RFLP patterns con-
stituted a single group by spoligotyping, matching the Beijing genotype.
Multidrug resistance, always involving isoniazid and rifampin, was seen in
34 (52.3%) of 65 isolates, with 28 belonging to the Beijing genotype.
Tuberculosis (TB) is an important health problem in
prison settings (1), where factors such as poor general health
of inmates, overcrowding, increased risk factors, delayed
case finding, and incomplete or inadequate therapeutic
intervention contribute to rapid spread (2) and high preva-
lence (e.g., 500 cases per 100,000 inmates in New York City
jails [3] and 2,283 per 100,000 inmates in the General Peni-
tentiary Hospital in Madrid, Spain [4]). In prisons of the
former Soviet Union, TB incidence is even higher (e.g., in
Siberia [5] or Russia as a whole [6,7]). TB incidence is also
associated with length of incarceration (3). Transmission
patterns are generally difficult to establish (8), and the rate
of unrecognized transmission may be quite high (9). Above
all, strains isolated in these settings are often multidrug
resistant (MDR) (10,11).
According to the International Committee of the Red
Cross (ICRC), the total number of inmates in the Azerbaijan
prison system is approximately 25,000. With 4,667 TB cases
per 100,000, the incidence in Azeri prisons is nearly 50 times
higher than the country average, and the mortality rate may
reach 24% (6). In June 1995, the ICRC implemented a TB
control program in the Central Penitentiary Hospital in
Baku, Azerbaijan, which was the only treatment center for
Azeri prisoners with TB. The program was based on directly
observed therapy, short course (DOTS), as recommended by
the World Health Organization (WHO [12]) and the Interna-
tional Union Against Tuberculosis and Lung Disease
(IUATLD [13]). After treatment failures were observed
despite completion of strictly supervised therapy, susceptibil-
ity testing of inmates’ M. tuberculosis isolates demonstrated
a high rate of multidrug resistance (11).
Several outbreaks of MDR-TB have been reported
worldwide from hospitals (affecting patients and health-care
workers [14]), the community (15), and prisons (4). In these
outbreaks, MDR-TB has predominantly affected immuno-
compromised patients, and disease was often caused by cer-
tain strains of  M. tuberculosis, in particular the W strain
(16-18). This strain and its many variants (e.g., subtypes W1
[17] and U [19]), form a family lineage that shares a common
genotype with the Beijing clone (20). At the molecular level,
they exhibit a closely related, unique multiband IS6110-
based restriction fragment-length polymorphism (RFLP)
pattern and contain 9 of 43 polymorphic spacer sequences in
the chromosomal DR locus by spoligotyping (21).
We report the genotypic characterization and spread of
predominantly MDR M. tuberculosis strains in a prison in
Azerbaijan. Along with IS6110-based RFLP, spoligotyping,
and drug-susceptibility profiles, we have determined the




At the beginning of the ICRC program, 65 male patients
19 to 55 years of age were included in the study. All were
from Azerbaijan, and their terms of imprisonment ranged
from 6 months to 20 years. Once diagnosed as having smear-
positive pulmonary TB, they were transferred to the Central
Penitentiary Hospital in Baku, the referral hospital for the
Azerbaijan prison system. No clinical histories were avail-
able for the time before the ICRC intervention. Personal
characteristics have largely been provided by the prisoners
themselves (Table). Patients were classified at admission on
the basis of their self-recorded anti-TB drug intake as nonre-
sponders (patients who were treated with single or multiple
drugs for >1 month and continued to be smear-positive
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Table. Characteristics of the cohort of prison inmates with tuberculosis, Azerbaijan
Strain no.
Age of patient 
(years)
Body mass 
index  Patient groupa Onset of symptoms
Previous treatment (before enrollment in 
ICRC program)b
7933 25 18.2 A Aug 1996 R,E,S
7887 40 -- A Jan 1995 H,R,E,S
7909 40 16.1 A Jun 1995 S (4 mo. in 1995) 
S (1 mo. in 1996)
7920 22 16.3 A Mar 1995 H(?),R(?),S
5695 22 17.2 B Feb 1996 S
5698 43 -- A 1976 R,E
7101 20 -- B Jan 1996 S
5691 26 -- A Feb 1995 S
7915 21 16.2 B Mar 1996 None
7922 33 16.1 A Spring 1996 H,R,E,S
5689 24 19.7 A 1993 H,R,E,S (1 to 2 mo.)
7924 40 17.4 B Apr 1996 H,R,E,S
7934 36 --c A Jul 1996 S
7908 32 16.1 B Mar 1996 R,E,S
7930 21 16 B Aug 1996 R,E,S
7935 23 17.3 B Mar 1996 R
7925 22 19.3 A Feb 1996 S (monotherapy initially); R,E,S 
(2 to 3 mo.)
7931 21 16 B Jul 1996 R,S
7914 34 15.7 A Nov 1995 R,E,S (not completed)
5713 25 15.6 B Dec 1995 H,R,E,S
7910 32 17.5 A Feb 1996 S,E (not completed)
7906 22 19.5 B Aug 1996 R,S
5719 32 -- C 1991 H,R,E,S (9 mo. in 1991)
7923 34 13.8 B Jan 1996 R,E,S
7899 33 15.8 A Jan 1996 H (4 mo.), R (10 d), E (4 mo.), S,Z (4 mo.) 
(not completed)
5684 29 17.2 A 1993 H,R,E,S (in 1994)
S (in 1995)
7900 ? 20.2 A Jul 1995 H,R,S (in 1995)
S (in 1996)
5697 19 17.4 B Mar 1996 none
5692 22 -- A Feb 1995 H,R,E,S
7916 32 18.2 A 1994 H,R,E,S,K (several <3-mo.intervals of 
treatment)
7932 22 18.1 C Nov 1993 H,R,E,S,K (several intervals of 
treatment: 1 mo., 4 mo., 12 mo.)
5700 34 18 B Feb 1996 none
5702 26 18.1 A Sep 1995 S
5706 23 -- B Feb 1996 S
5716 24 19 B Feb 1996 R,S
7888 30 -- A Oct 1994 H,R,E,K (<2 mo. in 1994) H,R (in 1995)
5693 26 17.2 B Jan 1996 S
5722 26 17.1 B Dec 1995 H,R,E,S,K
7895 19 18.5 B Jun 1996 H,R,S
5724 37 17.3 B Dec 1995 H,R,E,S
7886 46c -- A Mar 1995 R,E,S (not completed)
7917 55 -- C 1987 R,E,S (11 mo.)Research
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[group A; n = 30]), new cases (smear-positive patients who
had never been treated or were treated for <1 month [group
B; n = 31]), and relapsed cases (patients who had active TB
and were treated and considered clinically cured but became
smear-positive again [group C; n = 4]).
Microbiologic Diagnosis and Drug Susceptibility Testing
Sputum specimens were analyzed for the presence of
acid-fast bacilli (Ziehl-Neelsen staining) by the local microbi-
ology laboratory, which was supervised by the ICRC. Pro-
cessing of specimens, culture, and identification of  M.
tuberculosis were done in Zurich or Antwerp according to
standard procedures (22). Susceptibility testing of M. tuber-
culosis to primary drugs (isoniazid, RMP, ethambutol, and
pyrazinamide) plus streptomycin was performed in liquid
medium by the radiometric BACTEC 460 TB system (Becton
Dickinson, Sparks, MD) (23) and confirmed by the agar pro-
portion method (22).
Molecular Characteristics of RMP Resistance
All M. tuberculosis isolates were analyzed by the INNO-
LiPA-Rif TB Assay (Innogenetics, Ghent, Belgium) (24). This
reverse hybridization-based line probe assay carries one oli-
gonucleotide probe for the detection of M. tuberculosis com-
plex strains and nine probes to detect nucleotide changes in
the relevant part of the rpoB gene.
Molecular Epidemiology
PvuII-digested DNA of M. tuberculosis was probed with
the insertion element IS6110 according to the standardized
protocol of van Embden et al. (25), with some modifications
(26). “Cluster strains” had 100% identical RFLP patterns.
Cluster Analysis
IS6110-based RFLP patterns were analyzed by GelCom-
par software (Windows 95, version 4.0; Applied Math, Kort-
rijk, Belgium) with an HP ScanJet 4c (Hewlett Packard,
Greeley, CO; scanned at 190 dpi). The mobility of the IS6110
fragments was compared with the molecular weight marker
lambda-DNA EcoRI/HindIII (Roche Diagnostics, Rotkreuz,
Switzerland), which was used as external size marker. In
addition, the accuracy of the procedure was tested by com-
paring the IS6110 banding pattern of M. tuberculosis isolate
Mt14323, which was present on each autoradiograph. Pat-
terns were compared by the UPGMA clustering method with
the Dice coefficient (1.2%). Spoligotype patterns (27) gener-
ated from all 65 isolates were compared visually.
Table. (continued) Characteristics of the cohort of prison inmates with tuberculosis, Azerbaijan
Strain no.
Age of patient 
(years)
Body mass 
index  Patient group
a Onset of symptoms
Previous treatment (before enrollment in 
ICRC program)
b
7933 25 18.2 A Aug 1996 R,E,S
5718 20 17.6 B Oct 1995 H,K
7889 ? -- A ? ?
7921 22 19.4 B Jul 1996 S
7926 20 --c B Aug 1996 none
7918 33 16.4 B Jul 1996 H,R,E,S
7927 32 18.4 A Mar 1996 H,E,S (not completed)
7904 21 16.8 B May 1996 H,S
7929 47 26.3 A May 1996 R,E,S (not completed)
7894 28 17.3 B Apr 1996 None
7897 20 13.8 A Jan 1996 R,E,S (not completed)
7905 26 18.6 B Apr 1996 S
7907 19 14 B Dec 1995 H,S
7902 25 19.2 A 1995 H,S (6 mo.) R,E, (7 d)
5686 29 -- A May 1995 H,R,E,S (not completed)
5694 29 17.3 A Jan 1995 H,S (1 mo. in 1995) E,S (1 mo. in 1996)
5726 44 16.9 A ? H,R,E,S (3 to 4 mo. in 1991) H,R,E,S (in 
1995)
7911 34 17.9 B Mar 1995 R,E,S,K
5688 37 -- A Sep 1994 R,E,S
5687 41 20.3 B Feb 1996 E,S
5729 40 16.3 C 1994 R,S(3 mo. in 1994) S (in 1996)
7890 19 -- A 1994 H,E,S (3 mo. in 1994) R,E,S (in 1996)
5699 22 -- B Mar 1996 H,S
aGroup A = nonresponders; Group B = new cases (never treated or treated for <1 month); Group C = relapsed cases
bH, isoniazid; R, rifampin; E, ethambutol; S, streptomycin; Z, pyrazinamide; K, kanamycin
cPatient too weak to be weighedResearch
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Results
Except for two patients in whom the first symptoms of
TB had appeared 9 and 20 years previously, the patients had
recent onset of TB disease (Table). Most prisoners were sub-
stantially undernourished (as indicated by low body mass
indices) and in poor clinical condition, many with unilateral
or bilateral pulmonary infiltrates and cavities. Most of the
nonresponding patients (group A) had been treated inade-
quately before the ICRC intervention (Table).
Based on morphologic and biochemical characteristics,
all 65 isolates were identified as classical M. tuberculosis.
Hybridization of PvuII-digested chromosomal DNA with the
245-bp fragment of IS6110 resulted in variable patterns,
although to a limited degree (Figure 1). Within a cluster
(each cluster comprising a minimum of 2 and a maximum of
10 patients), isolates had identical IS6110 patterns. Overall,
we found 11 clusters containing a total of 33 isolates. Apart
from cluster 1, which consisted of 2 isolates with 10 IS6110
copies, the isolates belonging to clusters 2 to 11 were charac-
terized by 15 to 18 IS6110 fragments and similar banding
patterns (similarities of >90% for clusters 2 to 9 and >80%
for clusters 10 and 11 with the former group). In addition to
the 31 isolates of clusters 2 to 11, 15 other isolates of M.
tuberculosis displayed similar IS6110 patterns, differing in
the presence or absence of one or two bands or in the IS6110
fragment length (Figure 1). These 15 isolates were highly
related (>68%) to those of clusters 2 to 11. DNA fingerprints
of the 31 isolates in clusters 2 to 11 and the 15 closely associ-
ated isolates strongly resembled the Beijing genotype of M.
tuberculosis (Figure 1, asterisk).
Spoligotyping grouped those 46 isolates into one geno-
type with identical spoligotypes that lacked all but 9 of the
43 DR spacers and thus resembled the Beijing family of M.
tuberculosis. The remaining 19 isolates of the patient cohort
resulted in different, mostly individual spoligotypes (Figure
2). While cluster 1 was confirmed by spoligotyping, other iso-
lates, mostly with a high degree of similarity in their RFLP
patterns, were also grouped together (isolates 7887/5695/
7920; isolates 5691/5689; isolates 7922/7915; and isolates
7908/7935; Figure 2).
Regardless of Beijing or other types, the susceptibility
patterns differed, ranging from fully susceptible to resistant
to one or more drug(s). Overall, 52.3% of the strains isolated
from the cohort (Figure 2) and 60.9% (28/46 isolates) in the
group of Beijing type strains were MDR. While none of the
RMP-susceptible strains carried a mutation in the relevant
part of the  rpoB gene, all strains resistant to RMP (by
growth-based susceptibility testing) were correctly identified
by the INNO-LiPA-Rif assay. For 22 of them, the type muta-
tion was detected: D516V (R2; n = 1), H526Y (R4a; n = 2),
H526D (R4b; n = 1), and S531L (R5; n = 18). S531L was pre-
dominant in the Beijing family (17/28 RMPR isolates =
60.7%; Figure 2. MDR strains of M. tuberculosis were found
in 19 of 30 patients in group A, 14 of 31 patients in group B,
and 1 of 4 patients in group C. Full drug susceptibility was
also seen in all groups of patients (3 of 30 in group A, 7 of 31
in group B, and 1 of 4 in group C).
Conclusion
Analyzing the TB patients in the Central Penitentiary
Hospital in Baku was complicated by constraints and biases
inherent in the prison environment. Clinical information on
the prisoners was limited and mainly based on self-reported
data. Conclusions based on analysis of 65 of the approxi-
mately 300 TB patients in that hospital are largely fragmen-
tary and may not be truly representative. However, enrolling
more patients into our pilot study was not considered,
mainly because of frequent transfer of prisoners and high
mortality rates. When the DOTS program was implemented
by the ICRC, many of the TB patients were either untreated
or had received inadequate drug regimens for years.
Although we analyzed a limited number of patients, our
study demonstrates that most strains (70.8%) belonged to
the Beijing family of  M. tuberculosis and that multidrug
resistance was a serious problem (52.3%) in this setting. The
Beijing genotype, characterized by 15 to 18 IS6110 copies
and a specific spoligotype pattern, was identified in 10 of the
11 clusters (2 to 11) and included isolates of 31 patients, plus
Figure 1. Computer-generated lane maps of genomic fingerprints of
Mycobacterium tuberculosis strains isolated from the patient cohort
(n = 65). PvuII-digested chromosomal DNA was probed with IS6110.
Clusters 1 to 11 are indicated by vertical lines at the right margin.
Asterisk indicates strain 97-275 (Beijing clone, obtained from K.
Kremer, RIVM/NL) for comparison. Strains 7914 through 5687 show
the Beijing genotype restriction fragment-length polymorphism pat-
tern. The molecular weight marker and internal reference strain of
M. tuberculosis (Mt 14323) are not shown.Research
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isolates from an additional 15 patients that had a high simi-
larity with the cluster strains on IS6110-based DNA finger-
printing. Sharing most of the IS6110-containing restriction
fragments and the polymorphism associated with other
repetitive DNA elements (28), the Beijing clone of M. tuber-
culosis has been isolated predominantly from patients in the
People’s Republic of China and neighboring Asian countries
such as Mongolia, Korea, and Thailand (20). The emergence
of the Beijing clone is now also well documented in Vietnam:
Anh et al. have shown that 304 (54%) of 563 isolates studied
were of that genotype and associated with younger patients
and, hence, with active transmission (29).
In the three patient groups, only 11 isolates of M. tuber-
culosis were fully drug susceptible (2 patients in group A; 7
patients in B; and 1 patient in C). Dual resistance to iso-
niazid and streptomycin was seen in 10 cases (4 in A and 6 in
B). Multidrug resistance was particularly associated with
the Beijing genotype (28/46 = 61% versus 6/19 = 31% with
the non-Beijing type) and, as expected, most frequent in
patients of group A (19 in A, 14 in B, and 1 in C). For strains
of the Beijing group whose mutation types could be deter-
mined, substitution at ser531 (mutation type R5) predomi-
nated. Published reports indicate that this mutation is the
most common point mutation conferring RMP resistance
(30,31). Recently, Naroditskaya et al. (unpub. data) studied
40 MDR-TB isolates from inmates of a prison in Tomsk (Rus-
sia) and reported that as many as 77.5% of the isolates had a
substitution of ser531  >leu. Of these isolates, 15 had an
RFLP pattern (W148) specific for the so-called W-strain fam-
ily, which is highly drug-resistant and belongs to the phylo-
genetic lineage of the Beijing family. W and W-like strains
have been associated with large MDR-TB outbreaks in the
United States (16,17) and elsewhere (e.g., South Africa [19]).
With high disease and mortality rates, MDR outbreaks
caused by the W strain family and its variants have mainly
affected HIV-infected persons (17,18) but affect HIV-negative
persons as well (19,32). The HIV status of our cohort
remained unknown, since the prisoners had not been tested.
We assume that HIV infection has had little influence, since
its incidence in the general Azeri population is low (33).
The difficulty in establishing transmission links among
prisoners is well known. Although ample clinical information
about their patients was available, Jones et al. (8) were
unable to identify specific person-to-person lines of transmis-
sion among most inmates in a North American jail. Having
been unable to establish accurate links among inmates or to
define index patient(s) in the Baku Penitentiary Hospital,
we can only hypothesize possible modes of transmission; for
example, some patients may have contracted TB in the com-
munity long before they were imprisoned. Political con-
straints prevented us from studying TB strains in the Azeri
population, which would have allowed us to analyze the
molecular genetic composition of the strains circulating in
the community, as well as to estimate the prevalence of the
Beijing genotype strains. Acquisition of TB disease within
the prison walls is, however, more likely. Identical RFLP pat-
terns and spoligotypes, as well as identical susceptibility
patterns, including the same point mutation in the  rpoB
gene (e.g., isolates 5692, 5700, 5702, 5706, 7932, and 7888 of
cluster 5) suggest recent person-to-person transmission of
TB. Nevertheless, we could not establish that the isolates of
the large cluster carrying an S531L mutation are all derived
from the same index strain. Since this mutation is by far the
most frequent one, it could also have arisen independently in
some of these strains. 
Recent transmission within the prison is questionable
for those cluster strains that are identical by RFLP, spoligo-
type and susceptibility profiles but have distinct mutations
in the rpoB gene (e.g., isolate 7916 [cluster 5: DS2] versus all
other isolates of this cluster [R5]; isolates 7897 and 7907
[cluster 10: R4a and DS4]; isolates 5686 and 5694 [cluster 11:
DS2 and R5]). Thus, in all these cases TB is most likely not
the result of recent transmission from a single source, which
would require an RMP-susceptible progenitor strain. The
fact that different susceptibility patterns were detected
among the Beijing strains may indicate that transmission in
the prison primarily involved RMP-susceptible strains, with
resistance to RMP (and other drugs) evolving gradually in
individual patients.
From this study, several conclusions can be drawn:
MDR-TB is a substantial problem in Azeri prisons; the
Beijing clone of M. tuberculosis was found in all three patient
groups (nonresponders, new cases, and relapsed cases) and
had a high rate of multidrug resistance; modes of transmis-
sion remain unclear, i.e., TB may have been acquired in dif-
ferent ways (outside or inside the prison); and MDR-TB in
Figure 2. Spoligotypes of the 65 strains of M. tuberculosis analyzed,
drug susceptibility patterns, and type of mutation on the rpoB gene
conferring rifampin resistance (rpoB). H = isoniazid; R = rifampin; E
= ethambutol; Z = pyrazinamide; S = streptomycin. Black fields indi-
cate resistance; blank ones susceptibility. S = wild type (RMPS);
mutations (RMPR): DS1; DS2; DS3; DS4; DS5; R2; R4a; R4b; R5; ND
= not done. Group A = nonresponders; Group B = new cases; and
Group C = relapsed cases.Research
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this cohort may result from recent transmission in the
prison, but may also have evolved as a result of longstand-
ing, inadequate treatment regimens.
Unless WHO/IUATLD-recommended treatment schemes
are followed, the problem of TB, in particular of MDR-TB,
may become more widespread (8). In response, both WHO and
ICRC have developed guidelines for managing TB in prisons
(2). Special emphasis has to be put on settings where TB
strains have a high degree of resistance, since regimens with
first-line antibiotics may not be sufficient, as demonstrated by
Coninx et al. (34). To achieve TB control in prisons, multiple
goals need to be attained: efficient diagnosis to permit early
case finding, prompt initiation of standardized treatment,
monitoring of patient response to treatment, and provisions
for ample supply of anti-TB drugs that meet quality stan-
dards.
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